Summary
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know
Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
Adagene NASDAQ: ADAG Chief Strategy Officer Mickael Chane-Du outlined the company's clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizing the company's focus on improving the therapeutic index of CTLA-4 inhibition through its proprietary masking technology.
Adagene Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 28 | $110 | $99.96 | -$10.04 | -9.13% |
| JC John Canning Mi LLCreek Capital Advisors LLC | 199,610 | $418,133.03 | $712,607.7 | $294,474.67 | 70.43% |
 BRIANNE SHERGILL Exome Asset Management LLC | 736,845 | $1.39M | $2.63M | $1.24M | 88.89% |
| MO Matthew Okkerse Dauntless Investment Group LLC | 34,775 | $136,318 | $124,146.75 | -$12,171.25 | -8.93% |
Adagene Inc. (ADAG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Adagene Inc. ever had a stock split?
Adagene Inc. Profile
| Biotechnology Industry | Healthcare Sector | Peter Luo CEO | NASDAQ (NMS) Exchange | 005329107 CUSIP |
| CN Country | 138 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Adagene Inc. is a clinical stage biotechnology company specialized in the development and production of monoclonal antibody drugs targeting various cancers. Founded in 2011, the company combines innovative research and development strategies to create novel therapies. With its headquarters in Suzhou, China, Adagene is pioneering the innovation of antibody technology to address the unmet needs in cancer treatment. Its approach focuses on developing a diverse pipeline of product candidates that aim to tackle cancers through various mechanisms of action, underscoring its commitment to advancing cancer therapeutics.
Products and Services
ADG106: A human ligand-blocking agonistic anti-CD137 IgG4 monoclonal antibody currently in Phase 1b/2 clinical trials. It's designed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, aiming to enhance the anti-tumor immune response.
ADG126: A masked fully-human anti-CTLA-4 monoclonal antibody in Phase 1 clinical trial. This candidate focuses on the treatment of advanced/metastatic solid tumors, with a novel approach to modulate the immune system.
ADG116: Another anti-CTLA-4 mAb but with a ligand-blocking mechanism, in Phase 1b/2 clinical development. It targets advanced/metastatic solid tumors, proposing a different method of stimulating the immune system to combat cancer.
ADG104: An anti-PD-L1 monoclonal antibody in Phase 2 clinical development. It aims to inhibit the PD-L1 pathway, which is a crucial immune checkpoint in cancer evasion from immune surveillance, for various cancer types.
ADG125: A novel anti-CSF-1R monoclonal antibody in Phase I clinical trial. This product candidate is designed to target the CSF-1R pathway involved in tumor-associated macrophages, which can promote tumor growth and metastasis.
ADG206: A masked, Fc engineered anti-CD137 agonistic POWERbody. This innovative approach seeks to enhance immune response against tumors while potentially reducing side effects associated with CD137 targeting.
ADG153: A masked anti-CD47 IgG1 SAFEbody, currently in preclinical development. It is aimed at treating hematologic and solid tumors by targeting the "don't eat me" signal to promote phagocytosis of cancer cells.
ADG138: A novel HER2xCD3 POWERbody in preclinical for targeting HER2-expressing solid tumors. This product signifies a new approach to recruit and activate T cells specifically against cancer cells expressing HER2.
ADG152: A v POWERbody, in preclinical stage for the potential treatment of off-tumor toxicities. This represents a novel strategy to mitigate side effects of cancer therapies, enhancing patient safety and treatment tolerance.
In addition to these product candidates, Adagene is developing anti-CD28 bispecific POWERbody TCEs, further expanding its portfolio and capabilities in the fight against cancer.
